World Journal of Oncology, ISSN 1920-4531 print, 1920-454X online, Open Access
Article copyright, the authors; Journal compilation copyright, World J Oncol and Elmer Press Inc
Journal website https://www.wjon.org

Original Article

Volume 13, Number 4, August 2022, pages 185-189


Expression of Programmed Death Ligand 1 in Breast Cancer in Mexican Women

Table

Table 1. Characteristics of the Patients
 
PD-L1 expression in breast cancer tumorsTotal numberPositive cases% Positive casesNegative cases
Luminal A breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive at least ≥ 1% of tumor cells), HER2-negative (≤ 10% tumor cells membrane) and has low levels of the protein Ki-67 in tumor cells (≤ 14%). Luminal B breast cancer is hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive at least ≥ 1% in tumor cells), and either HER2-positive (at least >10% of tumor cells complete membrane) or HER2-negative with high levels of Ki-67 (> 14%). Triple-negative/basal-like breast cancer is hormone-receptor negative (estrogen-receptor and progesterone-receptor negative; < 1% of tumor cells) and HER2-negative (≤ 10% tumor cells membrane). PD-L1: programmed death ligand 1; TNM: tumor, node, metastases.
Tumoral size (TS)
  T1 (< 20 mm)26519%21
  T2 (> 20 mm - < 50 mm)301137%19
  T3 (> 50 mm)6350%3
  T4 (thoracic wall invasion or tumoral ulceration)11100%0
Total632043
Node metastases (PN)
  N0 (no metastases)36925%27
  N1 (micrometastases or metastases in 1 - 3 lymph nodes)13538%8
  N2 (metastases in 4 - 9 axillary lymph nodes4375%1
  N3 (metastases in 10 or more lymph nodes)10330%7
  Total632043
Immunochemistry
  Luminal A20315%17
  Luminal B HER2 positive4004
  Luminal B HER2 negative22836%14
  HER25240%3
  Triple negative12758%5
  Total632043
Histological grade
  Grade 16006
  Grade 231723%24
  Grade 3261350%13
  Total632043